Argus raises target for ICU Medical stock to USD 171.00

Published on 10/20/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ICUI is due to report on November 5, 2026. ICU Medical stock costs EUR 143.50 on October 20, 2026 at 9:10 p.m. CEST, with a USD 4.0 billion market value.

Analyst and reporting date

Argus raised its ICU Medical target to USD 171.00 on October 14, 2026.
ICU Medical is scheduled to report its third-quarter 2026 results on November 5, 2026.
ICU Medical stock costs EUR 143.50 at Lang & Schwarz on October 20, 2026 at 9:10 p.m. CEST.
ICU Medical had USD 4.0 billion in market capitalization and a trailing P/E of 136.28 on October 20, 2026.

ICUI, US44930G1076, Illustration mit AI erstellt.

Argus raised its price target for ICU Medical to USD 171.00 on October 14, 2026, according to Yahoo Finance. The target remains a separate Wall Street reference from the euro quotation: ICU Medical stock was at EUR 143.50 at Lang & Schwarz on October 20, 2026 at 9:10 p.m. CEST, after hours.

Target and earnings date

The Argus target gives investors a dated valuation marker while the next scheduled results provide the nearer test for ICU Medical's operating progress. MetaCap lists November 5, 2026 as the next earnings date and cites a consensus estimate of USD 1.75 in earnings per share for that report.

What does the latest quarter show?

In the second quarter of 2026, ICU Medical generated USD 551.70 million in revenue and reported diluted earnings per share of USD 0.76. Operating profit was USD 39.13 million, equal to a 7.09 percent operating margin. These figures come from the company's standardized quarterly financial record for the period ended June 30, 2026.

The company raised its full-year 2026 adjusted earnings-per-share guidance to USD 8.60-9.00 in August 2026. MarketBeat reported that second-quarter adjusted earnings per share of USD 2.37 exceeded the USD 1.91 consensus estimate and that revenue reached USD 547.88 million. The differing revenue figures reflect different reporting treatments and should not be combined as one quarterly measure.

Valuation remains demanding

On Nasdaq, ICUI was last at USD 160.84 on October 20, 2026 at 3:16 p.m. ET. Its same-day USD 113.37 to USD 192.85 52-week range places the quote below the yearly high, while market capitalization stood at USD 4.0 billion and the trailing P/E at 136.28. ICU Medical identifies itself as a Nasdaq-listed medical technology company developing products for infusion therapy and critical care.

Dates and investor signals

The next dated company event is the November 5, 2026 quarterly report. The August 6, 2026 second-quarter release also set the current adjusted earnings-per-share guidance range, making the upcoming report a test of that outlook rather than a new guidance event.

Stock perspective

The analyst target, the upcoming reporting date and the wide 52-week range point to three separate measures for evaluating the stock. The reported second-quarter operating margin of 7.09 percent also gives investors a concrete profitability figure to compare with future results.

The further course of trading is shown by the continuously updated real-time quote of ICU Medical stock.